GmbH, entered a strategic alliance to discover and develop
small molecule inhibitors for multiple targets in metabolic
disorders. The research alliance aims to develop therapeutic
small molecules that will address the unmet needs in diabetes
and obesity. Jubilant will provide drug discovery and early development services across computational, synthetic chemistry,
biology, GLP/ GMP services, to identify lead candidates and
demonstrate clinical proof of mechanism. The research for the
projects take place at R&D labs of Jubilant Biosys and Jubilant
Chemsys in Noida, India.
Sanofi and Innate Pharma entered a research collaboration
and licensing agreement to apply Innate Pharma’s new proprietary technology to the development of innovative bispecific
antibody formats engaging natural killer (NK) cells to kill tumor
cells through the activating receptor NKp46. Both companies will
work together on the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate Pharma
and Sanofi’s proprietary bispecific antibody format as well as
tumor targets. Sanofi will be responsible for the development,
manufacturing and commercialization of products resulting from
the research collaboration. Innate Pharma will be eligible to receive as much as $450 million in development and commercial
milestone payments, as well as royalties on net sales.
Recursion Pharmaceuticals entered a research agreement
with Sanofi Genzyme to deploy its drug repurposing plat-
form to identify new uses for Sanofi’s clinical stage molecules
across dozens of genetic diseases. Recursion generates hu-
man cellular models of many diseases and uses computer vi-
sion to extract thousands of morphological measures at the
level of individual cells. Molecules are then screened for their
ability to rescue phenotypic defects associated with each dis-
ease. Recursion has already used the platform to generate
an internal pipeline of candidates for a handful of genetic
diseases, with a lead asset nearing IND for the treatment of
Cerebral Cavernous Malformation. Sanofi will provide Re-
cursion with a number of small molecules, and Recursion
will screen these molecules across its extensive and rapidly
expanding library of genetic disease models. Sanofi Genzyme
will have the option to develop products targeting any new
Warp Drive Bio, a life sciences company developing therapeutics that exploit the molecules and mechanisms of nature, during
the year reached a milestone in the antibiotic discovery program
under its research collaboration with Sanofi. Sanofi assumed all
preclinical and clinical development efforts for the novel amino-glycoside antibiotic candidates discovered by Warp Drive. This
program is one of several natural product-based programs utilizing Warp Dive’s Genome Mining technology platform.
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for
Preparedness and Response in the U.S. Department of Health
and Human Services, awarded Sanofi a $37.6 million contract
to supply and manage inventory for Leukine. Sanofi Genzyme
is developing Leukine for the treatment of acute radiation syndrome, a serious illness that occurs in people exposed to high
doses of radiation. In 2013, Sanofi was awarded a $36.5 million
contract for late stage development and procurement of Leukine. Since then Sanofi Genzyme has conducted studies regarding the potential use of Leukine in patients acutely exposed to
myelosuppressive doses of radiation (Hematopoietic Syndrome
of Acute Radiation Syndrome). The company plans to submit a
supplemental Biologics License Application (sBLA) to the FDA
Sanofi also unveiled plans to develop and commercialize biologics in China through a partnership with JHL Biotech, a biopharma company with development and manufacturing facilities
in Wuhan and Taiwan. The two companies entered a strategic
alliance to develop and commercialize biologics in China with
potential international expansion.
As part of the deal, Sanofi invested $80 million in newly issued JHL shares and paid $21 million upfront to acquire exclusive rights for the proposed biosimilar of Rituximab and options
to certain JHL pipeline products. JHL will lead the development,
registration, and manufacturing activities, while Sanofi will lead
commercialization efforts in China. JHL is entitled to receive
milestones of as much as $236 million and sales royalties. CP
SANOFI INVESTS €340M TO EXPAND BIOLOGICS SITE IN BELGIUM
Additions to existing site will support production of monoclonal antibodies
During the year Sanofi unveiled plans for an approximately $340 million expansion at its site in Geel, Belgium, to drive
the future of biologics by expanding manufacturing and commercial capabilities in order to ensure quality, capacity, and scale.
Through the investment, Sanofi plans to adapt and expand existing production capabilities to support its pipeline of monoclonal antibod-
ies. Updates to the existing facility will include the development of new laboratories focused on quality control and manufacturing sciences.
Sanofi and its specialty care global business unit, Sanofi Genzyme, have already invested roughly $685 million in the Geel site, which
began industrial biotech activities in 2001. The site is currently responsible for the global production of a protein therapy for Pompe
disease, a rare, genetic muscular disease that is often fatal. The protein therapy is produced using cell cultures in large bioreactors, fol-
lowed by a purification process.
Through this latest investment, the state-of-the-art facility will add more than 8,000 square meters of manufacturing floor space, enabling the site to increase its overall production capacity and diversify to other drugs and therapeutic areas.
As part of the company’s strategic roadmap, Sanofi aims to launch several biologics in the upcoming years, pairing technology,
cutting-edge manufacturing and operations capabilities to deliver high-quality products that could improve patient outcomes.